Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trialDavid A. Palma, Suresh Senan, Robert Olson et al.|The Lancet|2019Cited by 1.9k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized StudyDaniel R. Gomez, John V. Heymach, Chad Tang et al.|Journal of Clinical Oncology|2019Cited by 1.3k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized TrialDavid A. Palma, Suresh Senan, Sashendra Senthi et al.|Journal of Clinical Oncology|2020Cited by 1.2k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R. Gomez, John V. Heymach, George R. Blumenschein et al.|The Lancet Oncology|2016Cited by 1.1k
Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysisDavid A. Palma, George Rodrigues, Suresh Senan et al.|International Journal of Radiation Oncology*Biology*Physics|2013Cited by 673